• Explore /
  • Poster
  • / Pivotal single-arm, phase 2 trial of tasurgratinib for patients with fibroblast growth factor receptor (FGFR)-2 gene fusion-positive cholangiocarcinoma (CCA).

Pivotal single-arm, phase 2 trial of tasurgratinib for patients with fibroblast growth factor receptor (FGFR)-2 gene fusion-positive cholangiocarcinoma (CCA).

Abstract Poster

Authors

null

Junji Furuse

Kanagawa Cancer Center, Yokohama, Japan

Junji Furuse , Bo Jiang , Takamichi Kuwahara , Taroh Satoh , Xuelei Ma , Sheng Yan , Hai-Tao Zhao , Masafumi Ikeda , Tongjian Cui , Takashi Sasaki , Zhiqiang Meng , Yousuke Nakai , Makoto Ueno , Yoshito Komatsu , Hiroaki Nagano , Chigusa Morizane , Setsuo Funasaka , Hiroki Ikezawa , Takuya Nakada , Lin Shen

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Track

Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT04238715

Citation

J Clin Oncol 42, 2024 (suppl 3; abstr 471)

DOI

10.1200/JCO.2024.42.3_suppl.471

Abstract #

471

Poster Bd #

B16

Abstract Disclosures

Similar Posters

First Author: Teresa Macarulla

First Author: Shubham Pant

First Author: Milind M. Javle

First Author: Yin-Hsun Feng